The Netherlands Cancer Institute

Rosetta Inpharmatics, Inc.

Merck Sharp + Dohme Corp.

Fred Hutchinson Cancer Center

Mao Mao

Peter S Linsley

Yudong He

HongYue Dai

Christopher J Roberts

Laura Johanna Van't Veer

Marc J Van De Vijver

Rene Bernards

Augustinus A M Hart

Hongyue Dai

Jerald P Radich

Janell M Schelter

A A M Hart

Aa M Hart

Laura Johanna VAN'T Veer

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

Diagnosis and prognosis of breast cancer patients

The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec&#x2122;) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec&#x2122; by modulating the expression or activity of these genes and/or their encoded proteins.

Genes associated with progression and response in chronic myeloid leukemia and uses thereof

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also provides methods of classifying and treating patients based on prognosis. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the diagnostic, prognostic and statistical methods disclosed herein.

Methods of assigning treatment to breast cancer patients

Growing community of inventors

Kirkland, WA, United States of America

Mao Mao